|
SIGNIFICANT VENDOR (Detail) (USD $)
|
3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2012
Gene Expression And Protein Production [Member]
FhCMB [Member]
|
Dec. 31, 2011
Gene Expression And Protein Production [Member]
FhCMB [Member]
|
Dec. 31, 2012
Gene Expression And Protein Production [Member]
FhCMB [Member]
|
Dec. 31, 2011
Gene Expression And Protein Production [Member]
FhCMB [Member]
|
Jun. 30, 2011
Gene Expression And Protein Production [Member]
FhCMB [Member]
|
Dec. 31, 2012
LicKM [Member]
FhCMB [Member]
|
Dec. 31, 2011
LicKM [Member]
FhCMB [Member]
|
Dec. 31, 2012
LicKM [Member]
FhCMB [Member]
|
Dec. 31, 2011
LicKM [Member]
FhCMB [Member]
|
Jun. 30, 2011
LicKM [Member]
FhCMB [Member]
|
Dec. 31, 2012
Yellow Fever Vaccine [Member]
FhCMB [Member]
|
Dec. 31, 2011
Yellow Fever Vaccine [Member]
FhCMB [Member]
|
Dec. 31, 2012
Yellow Fever Vaccine [Member]
FhCMB [Member]
|
Dec. 31, 2011
Yellow Fever Vaccine [Member]
FhCMB [Member]
|
Dec. 31, 2012
Yellow Fever Vaccine [Member]
Fiocruz [Member]
|
Dec. 31, 2011
Yellow Fever Vaccine [Member]
Fiocruz [Member]
|
Dec. 31, 2012
Yellow Fever Vaccine [Member]
Fiocruz [Member]
|
Dec. 31, 2011
Yellow Fever Vaccine [Member]
Fiocruz [Member]
|
Dec. 31, 2012
FhCMB [Member]
|
Dec. 31, 2011
FhCMB [Member]
|
Dec. 31, 2012
FhCMB [Member]
|
Dec. 31, 2011
FhCMB [Member]
|
Jun. 30, 2012
FhCMB [Member]
|
|
| Research and Development Arrangement with Federal Government, Description and Terms | The most recent amendment to the TTA requires: 1) the Company to make non-refundable payments to FhCMB aggregating $10,000,000, in installments of $2,000,000 per year over a five year period commencing in November 2009; and 2) FhCMB to expend at least equal amounts during the same timeframe for research and development services related to the commercialization of the Technology. | ||||||||||||||||||||||||||
| Related Party Transaction Minimum Annual Payment | $ 200,000 | $ 200,000 | |||||||||||||||||||||||||
| Related Party Transaction, Expenses from Transactions with Related Party | 0 | 300,000 | 0 | 564,000 | 0 | 60,000 | 0 | 271,000 | 0 | 234,000 | 390,000 | 554,000 | 550,000 | 474,000 | 1,100,000 | 1,100,000 | |||||||||||
| Interest Expense | 17,451 | 16,800 | 32,858 | 26,376 | 17,000 | 16,000 | 32,000 | 26,000 | |||||||||||||||||||
| Entity-Wide Accounts Payable, Related Party, Percentage | 89.00% | 89.00% | 87.00% | ||||||||||||||||||||||||
| Entity-Wide Accrued Expenses, Related Party, Percentage | 39.00% | 39.00% | 43.00% | ||||||||||||||||||||||||
| Related Party Transaction, Amounts of Transaction | 1,660,000 | 432,000 | |||||||||||||||||||||||||
| Revenue from Related Parties | $ 0 | $ 234,000 | $ 390,000 | $ 554,000 | |||||||||||||||||||||||